SARS1
Serine--tRNA ligase, cytoplasmic
Also known as: SARS, SERS, SYSC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P49591
- Gene
- SARS1
- Ensembl
- ENSG00000031698
- Chromosome
- 1
- Canonical length
- 514 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown. [provided by RefSeq, Jul 2010]
Canonical amino-acid sequenceUniProt
514 residues, UniProt reviewed canonical sequence.
>P49591|SARS1
1 MVLDLDLFRV DKGGDPALIR ETQEKRFKDP GLVDQLVKAD SEWRRCRFRA DNLNKLKNLC
61 SKTIGEKMKK KEPVGDDESV PENVLSFDDL TADALANLKV SQIKKVRLLI DEAILKCDAE
121 RIKLEAERFE NLREIGNLLH PSVPISNDED VDNKVERIWG DCTVRKKYSH VDLVVMVDGF
181 EGEKGAVVAG SRGYFLKGVL VFLEQALIQY ALRTLGSRGY IPIYTPFFMR KEVMQEVAQL
241 SQFDEELYKV IGKGSEKSDD NSYDEKYLIA TSEQPIAALH RDEWLRPEDL PIKYAGLSTC
301 FRQEVGSHGR DTRGIFRVHQ FEKIEQFVYS SPHDNKSWEM FEEMITTAEE FYQSLGIPYH
361 IVNIVSGSLN HAASKKLDLE AWFPGSGAFR ELVSCSNCTD YQARRLRIRY GQTKKMMDKV
421 EFVHMLNATM CATTRTICAI LENYQTEKGI TVPEKLKEFM PPGLQELIPF VKPAPIEQEP
481 SKKQKKQHEG SKKKAAARDV TLENRLQNME VTDALocalizationUniProt · AlphaFold · HPA
Whether an antibody against SARS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 141 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 141 nTPM
- thyroid gland: 131 nTPM
- cerebral cortex: 121 nTPM
- blood vessel: 108 nTPM
- skeletal muscle: 106 nTPM
- stomach: 105 nTPM
Single-cell type
- migrating cytotrophoblasts: 250 nCPM
- syncytiotrophoblasts: 224 nCPM
- cytotrophoblasts: 221 nCPM
- extravillous trophoblasts: 189 nCPM
- esophageal apical cells: 188 nCPM
- esophageal suprabasal cells: 185 nCPM
Immune cell
- total PBMC: 460 nTPM
- T-reg: 302 nTPM
- naive B-cell: 254 nTPM
- naive CD4 T-cell: 247 nTPM
- MAIT T-cell: 240 nTPM
- memory CD4 T-cell: 239 nTPM
Brain region
- cerebral cortex: 139 nTPM
- hypothalamus: 136 nTPM
- pons: 131 nTPM
- white matter: 128 nTPM
- medulla oblongata: 123 nTPM
- midbrain: 113 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SARS1.
Disease | AllUniProt
Conditions SARS1 is implicated in, by any mechanism.
- Neurodevelopmental disorder with microcephaly, ataxia, and seizures (NEDMAS) MIM:617709
Disease | GeneticClinVar
3 pathogenic / likely-pathogenic of 88 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Neurodevelopmental disorder with microcephaly, ataxia, and seizures
- Cerebral arteriovenous malformation
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.21
- gnomAD pLI
- 1
- DepMap mean gene effect
- -2.58
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cytoplasmic translation
- negative regulation of angiogenesis
- negative regulation of transcription by RNA polymerase II
- selenocysteine incorporation
- seryl-tRNA aminoacylation
- translation
- tRNA modification
- negative regulation of vascular endothelial growth factor production
Molecular functions
- ATP binding
- enzyme binding
- molecular adaptor activity
- protein homodimerization activity
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- serine-tRNA ligase activity
- tRNA binding
- selenocysteine-tRNA ligase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminoacyl-tRNA synthetase, class II (G/ P/ S/T)
- Serine-tRNA ligase, type1
- Aminoacyl-tRNA synthetase, class II
- Class I and II aminoacyl-tRNA synthetase, tRNA-binding arm
- Serine-tRNA ligase catalytic core domain
- Serine-tRNA synthetase, type1, N-terminal domain superfamily
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- tRNA synthetase class II core domain (G, H, P, S and T)
- Serine-tRNA synthetase, type1, N-terminal
- Seryl-tRNA synthetase N-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SARS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SARS1 as an antibody target. Whether an autoantibody or antibody against SARS1 could matter depends on whether native SARS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SARS1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SARS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...